Carcinoid Tumor
📧 Sign up to get email alerts when something new happens for Carcinoid Tumor.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-12-22FDA Approved: OCTREOSCAN — Supplemental Application (Curium US LLC)
The FDA approved a supplemental application for OCTREOSCAN (Indium-111 pentetreotide) submitted by Curium US LLC.
-
CLINICAL_TRIALS trial_result · 2020-08-04Clinical Trial Update: Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy [Phase 2]
Phase 2 clinical trial update investigating peptide receptor radiotargeted therapy for carcinoid heart disease and carcinoid syndrome/tumor.
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: GA-68 DOTA-TOC of Somatostatin Positive Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial update for GA-68 DOTA-TOC targeting somatostatin receptors in neuroendocrine tumors and related malignancies, with …
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe [Phase 2]
Phase 2 RAMSETE trial evaluating RAD001 (everolimus) in advanced and metastatic silent neuroendocrine tumors; results were posted in January…
-
CLINICAL_TRIALS trial_result · 2018-04-13Clinical Trial Update: Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion [Phase 3]
A Phase 3 clinical trial evaluating the effect of oral 5-HTP on urinary 5-HIAA excretion was terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-12-27Clinical Trial Update: AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial of AMG 479 in advanced carcinoid tumors and pancreatic neuroendocrine tumors has completed, with results posted in 2017.
-
CLINICAL_TRIALS withdrawal · 2017-08-23Clinical Trial Update: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
The clinical trial evaluating 68Ga DOTA-TATE PET/CT in somatostatin receptor–positive tumors is no longer available.
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: A Study of Axitinib in Advanced Carcinoid Tumors [Phase 2]
Phase 2 trial update for axitinib in advanced carcinoid tumors has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-05-03Clinical Trial Update: 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) [Phase 1]
A Phase 1 trial evaluating the PET imaging agent 68Ga-DOTATOC for somatostatin receptor–positive neuroendocrine tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: EPO906 in Carcinoid and Other Neuroendocrine Tumors [Phase 2]
Phase 2 trial of EPO906 (irofulven) in carcinoid tumors and other neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2016-10-19Clinical Trial Update: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors [Phase 1]
A Phase 1 trial assessing the combination of pasireotide and RAD001 (everolimus) in patients with advanced neuroendocrine tumors has complet…
-
FDA approval · 2015-06-01FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) filed by Ipsen Biopharmaceuticals, Inc., updating the …
-
CLINICAL_TRIALS trial_result · 2015-05-20Clinical Trial Update: RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid [Phase 2]
A Phase 2 trial of RAD001 (everolimus) for pheochromocytoma, extra-adrenal paraganglioma, and non-functioning carcinoid has completed.
-
FDA approval · 2014-05-19FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) from Novartis, resulting in an updated labeling to re…
-
CLINICAL_TRIALS trial_result · 2014-04-29Clinical Trial Update: Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors [Phase 1]
Phase 1 trial update of sorafenib in combination with RAD001 (everolimus) in patients with advanced neuroendocrine tumors, including carcino…
-
CLINICAL_TRIALS trial_result · 2014-01-17Clinical Trial Update: 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating 68Ga-DOTATATE PET imaging in patients with neuroendocrine tumors to assess diagnostic performance.
-
CLINICAL_TRIALS trial_result · 2013-07-30Clinical Trial Update: Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease [Phase 3]
Phase 3 trial comparing pasireotide long-acting release to octreotide long-acting release in patients with metastatic carcinoid disease; the…
-
CLINICAL_TRIALS trial_result · 2012-03-12Clinical Trial Update: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor [Phase 3]
A Phase 3 trial evaluating the combination of everolimus and octreotide in patients with advanced carcinoid tumor has completed and posted r…
-
CLINICAL_TRIALS trial_result · 2011-10-12Clinical Trial Update: ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid [Phase 1]
Phase 1 clinical trial of Ultratrace iobenguane I-131 in patients with malignant pheochromocytoma, paraganglioma, or metastatic carcinoid ha…
-
CLINICAL_TRIALS trial_result · 2011-06-15Clinical Trial Update: Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma [Phase 2]
Phase 2 clinical trial update of Quarfloxin (CX-3543) in patients with low to intermediate grade neuroendocrine tumors completed.
-
CLINICAL_TRIALS trial_result · 2011-06-15Clinical Trial Update: 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors [Phase 3]
This is a Phase 3 clinical trial update evaluating 123I‑MIBG scintigraphy for evaluating patients with suspected neuroendocrine tumors, incl…
-
CLINICAL_TRIALS trial_result · 2010-08-04Clinical Trial Update: Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor [Phase 1, Phase 2]
A Phase 1/2 clinical trial update evaluating the safety and tolerability of RAD001 (everolimus) daily in Chinese patients with advanced pulm…
-
CLINICAL_TRIALS trial_result · 2010-03-10Clinical Trial Update: A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors [Phase 2]
Phase 2 clinical trial evaluating the safety and efficacy of combining Panzem NCD with Avastin in metastatic carcinoid tumors has completed.
-
CLINICAL_TRIALS trial_result · 2010-02-25Clinical Trial Update: Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features [Phase 1]
A Phase 1 safety study update evaluating Seneca Valley Virus in patients with solid tumors exhibiting neuroendocrine features.
-
FDA approval · 2009-03-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Octreotide acetate from Hikma Pharmaceuticals USA Inc., updating the regulatory status of the ge…